Pitavastatin and simvastatin have both been shown to inhibit breast cancer proliferation in vitro and in vivo by inhibiting RhoA, NF-κB, Arf6 or PI3K signaling44–47. The gene discussed is RHOA; the disease is breast carcinoma.